Day: March 6, 2024

HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced its operating and financial results for the fourth quarter and full year of 2023. Whitestone creates neighborhood center communities in its high-quality open-air shopping centers that it acquires, owns, manages, develops, and redevelops primarily in some of the largest, fastest-growing, high-household-income markets in the Sunbelt. “I am proud of the work and dedication of the Whitestone team in executing our strategic priorities and steadfastly serving our tenants and our neighborhood communities. We finished the year on a very strong note: hitting record occupancy of 94.2%, GAAP leasing spreads of nearly 22% and achieving a year-over-year revenue increase in excess of 5%. We initiated 2024 Core FFO per share...

Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024 by our partner, Jazz Pharmaceuticals Initiation of Phase 3 confirmatory trial for zanidatamab as first-line treatment in BTC by our partner Jazz Pharmaceuticals Expected submission of BLA for zanidatamab with the National Medical Products Administration (NMPA) in China for treatment of HER2-amplified inoperable and advanced or metastatic BTC in 2H 2024 by our partner BeiGene Targeting HERIZON-GEA-01 pivotal Phase 3...

Fourth Quarter Net Income Attributable to Cohen & Company Inc. of $4.5 Million, or $2.97 per Diluted Share Fourth Quarter Adjusted Pre-Tax income of $16.0 Million, or $2.88 per Diluted Share Board Declares Quarterly Dividend of $0.25 per Share PHILADELPHIA and NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) — Cohen & Company Inc. (NYSE American: COHN), a financial services firm specializing in an expanding range of capital markets and asset management services, today reported financial results for its fourth quarter and full year ended December 31, 2023. Summary Operating Results    Three Months Ended   Twelve Months Ended($ in thousands) 12/31/23   9/30/23   12/31/22   12/31/23   12/31/22                   Net trading $ 7,809     $ 7,491     $ 9,644     $ 30,926     $ 40,009  Asset management   1,919       1,788       1,761       7,337       9,004  New...

Record full year 2023 revenue of $148.7 million increased 22% compared to prior year WARSAW, Ind., March 06, 2024 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 & Recent Business HighlightsHelped nearly 20,000 children in the fourth quarter 2023 and approximately 82,000 for full year 2023, bringing the total to over 710,000 since the inception of OrthoPediatrics, including Boston Orthotics & Prosthetics, the combined organizations have helped more than 1.0 million kids Generated total revenue of $37.6 million for fourth quarter 2023, up 21% from $31.0 million in...

CERRITOS, Calif., March 06, 2024 (GLOBE NEWSWIRE) — GEN Restaurant Group, Inc. (“GEN” or the “Company”), owner of GEN Korean BBQ, a fast-growing cook-it-yourself casual dining concept, today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights for the Fourth quarter ended December 31, 2023 were as follows:Revenue increased 10.4% to $45.1 million, compared to $40.8 million in the fourth quarter of 2022; Comparable restaurant sales decreased 1.7% as compared to the fourth quarter in 2022; Income from operations was $(0.9) million and (2.0)% of revenue; Restaurant-level adjusted EBITDA(1) was $7.2 million and 16.0% of revenue; Net Income (loss) was $(0.2) million and (0.4%) of revenue; Adjusted EBITDA(1) was $1.6 million and 3.6% of revenue inclusive of pre-opening expense of approximately...

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023. Full Year 2023 and Recent Corporate HighlightsAnnounced positive statistically significant top-line data from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi syndrome (PWS) in September 2023.The study met its primary endpoint, demonstrating a highly statistically significant difference in change from baseline in HQ-CT total score for DCCR compared to placebo (p=0.0022).Secondary...

WOODCLIFF LAKE, N.J., March 06, 2024 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced results for the fourth quarter and year ended December 31, 2023. For the quarter ended December 31, 2023, Hudson reported revenues of $44.9 million, a decrease of 5% compared to revenues of $47.4 million in the comparable 2022 period. The decrease is primarily related to decreased selling prices for certain refrigerants, offset by slightly higher volume. Gross margin in the fourth quarter of 2023 was 31%, compared to 32% in the fourth quarter of 2022. Hudson reported operating income of $4.7 million in the fourth quarter of 2023, compared to operating income of $7.1 million in the prior year period. The Company recorded net income of $3.9 million or $0.09 per basic and $0.08 per diluted share in the fourth quarter of 2023,...

Expanded Gross Margin in Fourth Quarter 2023 by 180 bps, compared to Fourth Quarter 2022 Grew Fiscal Year 2023 Net Cash Provided by Operating Activities by 149%, $9.2 million from Fiscal Year 2022 Grew Fiscal Year 2023 Free Cash Flow by 867%, $10.3 million from Fiscal Year 2022 CHICO, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. Crystal Landsem, CEO of Lulus, said: “We continue to be focused on delivering on our core strategic pillars of improving Lulus brand awareness and broadening our reach and customer touchpoints, and are encouraged by the sequential upward revenue momentum building at the end of 2023 and into the first two months of 2024. Strong...

HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today its operating and financial results for the fourth quarter and full-year 2023, year-end 2023 proved reserves and guidance for full-year 2024. Key Highlights2024 strategic updates include:Commenced the Beta development program, with the first well spud in March 2024 Initiated the previously announced Bairoil marketing processDuring the fourth quarter of 2023, the Company:Achieved average total production of 20.8 MBoepd Generated net cash provided by operating activities of $28.4 million and net income of $43.6 million Delivered Adjusted EBITDA of $25.2 million Generated $14.4 million of free cash flowFor full-year 2023, the Company:Achieved average total production of 20.5 MBoepd Generated...

SAN JOSE, Calif., March 06, 2024 (GLOBE NEWSWIRE) — Infinera Corporation (NASDAQ: INFN) (“Infinera” or the “Company”) today released preliminary financial results for its fourth quarter ended December 30, 2023. For the fourth quarter,Preliminary revenue is expected to be $435 million to $452 million, compared to the Company’s prior outlook of $421 million to $451 million. The resulting preliminary GAAP gross margin is expected to be 38.0% to 40.0%, compared to the Company’s prior outlook of 37.3% to 40.4%. The resulting preliminary GAAP operating margin is expected to be 0.0% to 3.0%, compared to the Company’s prior outlook of 0.7% to 5.0%. The resulting preliminary GAAP net income (loss) per diluted share is expected to be ($0.02) to $0.04, compared to the Company’s prior outlook of ($0.04) to $0.04. Preliminary...